 |
|
Randomized, Placebo-Controlled Study of Tolcapone in Patients With Fluctuating Parkinson Disease Treated With Levodopa-Carbidopa
Charles H. Adler, MD, PhD;
Carlos Singer, MD;
Christopher O'Brien, MD;
Robert A. Hauser, MD;
Mark F. Lew, MD;
Kenneth L. Marek, MD;
Ernest Dorflinger, MD;
Simon Pedder, PhD;
Dennis Deptula, PhD;
Kisook Yoo, PHD;
for the Tolcapone Fluctuator Study Group III
Arch Neurol. 1998;55:1089-1095.
Objective To assess the efficacy and tolerability of the catechol-O-methyltransferase inhibitor tolcapone in reducing "off/on" fluctuations in levodopa-treated parkinsonian patients.
Design A randomized, double-blind, placebo-controlled, parallel-group study.
Setting Fifteen Parkinson disease clinics.
Patients Two hundred fifteen referred outpatients with Parkinson disease who showed predictable end-of-dose motor fluctuations that were not controlled by a stable levodopa-carbidopa (Sinemet) regimen of at least 4 weeks' duration.
Interventions In addition to their usual levodopa-carbidopa regimen, patients received placebo or tolcapone, 100 or 200 mg, 3 times daily orally for 6 weeks.
Primary Outcome Measure Change in daily off/on time.
Results Tolcapone, 100 and 200 mg 3 times daily, reduced off time by 2.0 and 2.5 hours per day, respectively, and increased on time by 2.1 and 2.3 hours per day, respectively (P<.001 vs placebo). Investigators' global measures of disease severity indicated that significantly more tolcapone-treated patients had reduced wearing off and symptom severity (P<.001 vs placebo). No significant change in quality-of-life measures occurred. Clinical improvements occurred despite a reduction in total daily levodopa dose of 185.5 mg (23%) in the tolcapone, 100 mg 3 times daily, group and 251.5 mg (29%) in the 200 mg 3 times daily group. Principal adverse events (mainly dyskinesia and nausea) were levodopa related, were not treatment limiting, and were seldom reported as reasons for withdrawal. The frequency of withdrawals because of adverse events was similar in all groups (3% to 7%).
Conclusions Tolcapone was well tolerated and substantially increased on time and reduced off time in patients with fluctuating Parkinson disease. Additionally, levodopa requirements were significantly decreased.
From the Parkinson's Disease and Movement Disorders Center, Mayo Clinic, Scottsdale, Ariz (Dr Adler); Movement Disorders Center, University of Miami, Miami, Fla (Dr Singer); Colorado Neurological Institute Movement Disorders Center, Englewood (Dr O'Brien); Department of Neurology, University of South Florida, Tampa (Dr Hauser); Department of Neurology, Division of Movement Disorders, University of Southern California, Los Angeles (Dr Lew); Yale Movement Disorders Center, Yale University, New Haven, Conn (Dr Marek); and Hoffmann-La Roche, Nutley, NJ (Drs Dorflinger, Pedder, Deptula, and Yoo).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Pharmacologic Options for Treatment of Levodopa-Associated ``Wearing Off''
Waters and Chen
Journal of Pharmacy Practice 2008;21:254-261.
ABSTRACT
Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease
Lees et al.
J. Neurol. Neurosurg. Psychiatry 2007;78:944-948.
ABSTRACT
| FULL TEXT
Management of motor complications in Parkinson's disease
Dewey
Neurology 2004;62:S3-S7.
ABSTRACT
| FULL TEXT
Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study
Brooks and Sagar
J. Neurol. Neurosurg. Psychiatry 2003;74:1071-1079.
ABSTRACT
| FULL TEXT
Relevance of motor complications in Parkinson's disease
Adler
Neurology 2002;58:S51-56.
ABSTRACT
| FULL TEXT
Catechol-O-methyltransferase (COMT): Biochemistry, Molecular Biology, Pharmacology, and Clinical Efficacy of the New Selective COMT Inhibitors
Mannisto and Kaakkola
Pharmacol. Rev. 1999;51:593-628.
ABSTRACT
| FULL TEXT
|
